As the number of iPSC-based therapies in clinical development is increasing, the industry is seeing significant advancement following decades of the industry’s iPSC development efforts. In this webinar transcript, which was hosted on Cell & Gene Therapy Insights in March 2024, industry experts delve into the critical aspects of reshaping the future landscape of iPSC-based therapies.
Since the commercialization of the first CAR T cell therapies, these revolutionary treatments have reshaped the landscape of cancer therapy, offering unprecedented hope to patients with hematologic malignancies. Listen to the panel of industry and healthcare sector experts discuss the critical intersection of commercialization strategies and manufacturing technology in advancing the next wave of CAR T cell therapies to market.
Induced pluripotent stem cell (iPSC)-based therapies offer advantages in their potential to address clinical applicability and scalable manufacturing to meet patient demand. As the number of iPSC-based therapies in clinical development is increasing, the industry is seeing significant advancement following decades of development efforts. Despite these noteworthy strides, there are still many existing dilemmas to address for sustained progress and commercial viability. Hear from experts as they delve into critical aspects to reshape the landscape of iPSC-based therapies.
Natural killer (NK) cells play a critical role in the body's immune system. Their unique ability to identify and destroy abnormal cells, while leaving healthy cells unharmed, make them a promising treatment option for various cancers and infectious diseases. NK and CAR-NK cells represent an attractive alternate modality with the potential to address shortcomings experienced by T cell and CAR T-based therapies. Hear from industry experts as they discuss industry challenges and opportunities around NK cell therapy development and more.
